Peptides Similar to Zilucoplan
Compare Zilucoplan with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Pegcetacoplan: Both are peptide-based complement inhibitors, but target different components. Zilucoplan inhibits C5 (terminal pathway); pegcetacoplan inhibits C3 (all three pathways). Both are subcutaneously administered and approved for complement-mediated diseases.
- •Rusfertide: Both are synthetic peptides in the Immune category with subcutaneous administration for autoimmune/hematologic conditions.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Zilucoplan (current) | - | - |
| Pegcetacoplan | Both are peptide-based complement inhibitors, but target different components. Zilucoplan inhibits C5 (terminal pathway); pegcetacoplan inhibits C3 (all three pathways). Both are subcutaneously administered and approved for complement-mediated diseases. | Different complement targets (C5 vs C3), different indications (gMG vs PNH/GA), different molecular architectures (macrocyclic vs PEGylated cyclic), different dosing frequencies (daily vs twice weekly or monthly). |
| Rusfertide | Both are synthetic peptides in the Immune category with subcutaneous administration for autoimmune/hematologic conditions. | Completely different mechanisms: zilucoplan inhibits complement C5 for neuromuscular disease, while rusfertide mimics hepcidin for iron metabolism in polycythemia vera. Different targets, indications, and disease areas. |
PegcetacoplanBoth are peptide-based complement inhibitors, but target different components. Zilucoplan inhibits C5 (terminal pathway); pegcetacoplan inhibits C3 (all three pathways). Both are subcutaneously administered and approved for complement-mediated diseases.
Differences
Different complement targets (C5 vs C3), different indications (gMG vs PNH/GA), different molecular architectures (macrocyclic vs PEGylated cyclic), different dosing frequencies (daily vs twice weekly or monthly).
Advantages
Selective C5 inhibition preserves upstream complement functions important for immune defense. Once-daily self-injection for gMG convenience.
Disadvantages
Limited to terminal pathway blockade; does not address extravascular hemolysis in PNH (where C3 inhibition is relevant).
RusfertideBoth are synthetic peptides in the Immune category with subcutaneous administration for autoimmune/hematologic conditions.
Differences
Completely different mechanisms: zilucoplan inhibits complement C5 for neuromuscular disease, while rusfertide mimics hepcidin for iron metabolism in polycythemia vera. Different targets, indications, and disease areas.
Advantages
Zilucoplan is FDA-approved (October 2023); addresses a fundamentally different complement-mediated mechanism in gMG.
Disadvantages
Carries meningococcal infection risk due to complement inhibition; requires REMS program enrollment.
Complement Inhibitors Related to Zilucoplan#
Zilucoplan belongs to the growing class of complement inhibitors used for autoimmune and hematologic conditions. The complement system can be targeted at multiple levels, and each approach has distinct therapeutic implications. The most relevant comparisons are with other C5 inhibitors (eculizumab, ravulizumab) and with the C3 inhibitor pegcetacoplan.
Eculizumab (Soliris)#
Eculizumab is a humanized monoclonal antibody that binds C5 and prevents its cleavage. It was the first complement inhibitor approved for clinical use (2007 for PNH, later for aHUS, gMG, and NMOSD).
Mechanism comparison: Both zilucoplan and eculizumab inhibit C5, but zilucoplan has a dual mechanism (C5 cleavage inhibition plus C5b-C6 blockade) while eculizumab acts solely by preventing C5 cleavage. Both are approved for gMG.
Administration comparison: The key practical difference is route and frequency. Eculizumab requires biweekly intravenous infusions at an infusion center, while zilucoplan is self-administered daily at home via subcutaneous injection.
| Parameter | Zilucoplan | Eculizumab |
|---|---|---|
| Class | Macrocyclic peptide | Humanized mAb |
| Molecular weight | ~3.5 kDa | ~148 kDa |
| Route | SC self-injection | IV infusion |
| Frequency | Daily | Every 2 weeks |
| Setting | Home | Infusion center |
| C5 mechanism | Dual (cleavage + C5b-C6) | Cleavage only |
| MG indication | gMG (AChR+) | gMG (AChR+) |
| Other indications | None currently | PNH, aHUS, NMOSD |
Ravulizumab (Ultomiris)#
Ravulizumab is an engineered anti-C5 monoclonal antibody with an extended half-life compared to eculizumab, allowing dosing every 8 weeks. It is approved for PNH, aHUS, gMG, and NMOSD.
Key differences: Ravulizumab offers less frequent dosing than eculizumab (every 8 weeks vs every 2 weeks) but still requires IV infusion at a healthcare facility. Zilucoplan offers the convenience of daily home self-injection. Ravulizumab has a broader indication portfolio.
Pegcetacoplan (Empaveli/Syfovre)#
Pegcetacoplan is a PEGylated cyclic peptide that targets complement C3, which is upstream of C5. This provides broader complement inhibition, blocking all three activation pathways at their convergence point.
Mechanism comparison: C3 inhibition (pegcetacoplan) is more comprehensive than C5 inhibition (zilucoplan), addressing both intravascular and extravascular hemolysis in PNH. However, C3 inhibition also suppresses opsonization and other upstream complement functions, potentially increasing susceptibility to encapsulated bacteria.
Indication differences: Pegcetacoplan is approved for PNH and geographic atrophy, while zilucoplan is approved for gMG. They address fundamentally different complement-mediated diseases.
Efgartigimod (Vyvgart)#
Efgartigimod is an FcRn antagonist that reduces circulating IgG antibody levels, including the pathogenic AChR antibodies in gMG. It represents a fundamentally different therapeutic approach -- reducing the antibody trigger rather than blocking the complement effector pathway.
Key differences: Efgartigimod targets the antibody-mediated component of gMG pathogenesis, while zilucoplan targets the complement-mediated effector mechanism. They could theoretically be complementary, addressing different nodes in the disease pathway.
Summary Comparison#
| Feature | Zilucoplan | Eculizumab | Ravulizumab | Pegcetacoplan | Efgartigimod |
|---|---|---|---|---|---|
| Target | C5 | C5 | C5 | C3 | FcRn |
| Type | Macrocyclic peptide | mAb | Engineered mAb | PEGylated cyclic peptide | Fc fragment |
| Route | SC daily | IV Q2W | IV Q8W | SC Q3D or IVT monthly | IV Q1W |
| Self-admin | Yes | No | No | Yes (SC) | No |
| MW | ~3.5 kDa | ~148 kDa | ~148 kDa | ~43.5 kDa | ~54 kDa |
| gMG approved | Yes | Yes | Yes | No | Yes |
| PNH approved | No | Yes | Yes | Yes | No |
Related Reading#
Frequently Asked Questions About Zilucoplan
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer